Barnett Sean J, Katz Aviva
Pediatric General and Thoracic Surgery, Department of Surgery, Boonshoft School of Medicine, Dayton Children's Hospital, Dayton, OH; Kaleidoscope, Inc., Cincinnati, OH.
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA; Department of Pediatric General and Thoracic Surgery, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA.
Semin Pediatr Surg. 2015 Jun;24(3):141-4. doi: 10.1053/j.sempedsurg.2015.02.014. Epub 2015 Mar 3.
As the culture of medical practice has evolved, so has the relationship between the physician and patient. This is decidedly true with regards to the introduction of innovative therapies, especially in the surgical arena. A critical challenge is identifying and defining innovative therapy. Is the proposed treatment an incremental change, a research proposal, or more commonly someplace in between? This gray area creates a transition zone commonly referred to as innovative therapy. Given the complexities of the current landscape of innovation, innovation therapy committees may provide a mechanism to help to guide both physicians and patients through such difficult topics as the process of informed consent, managing conflicts of interest, and how to evaluate the outcomes of innovative therapies. As surgical innovation remains critical to the advancement of care, it must occur in a transparent partnership with patients, under the eye of guiding entities, aimed at ultimately improving outcomes and care.
随着医疗实践文化的演变，医生与患者之间的关系也在发生变化。在引入创新疗法方面，尤其是在外科领域，确实如此。一个关键挑战是识别和定义创新疗法。提议的治疗方法是渐进式改变、研究提议，还是更常见的介于两者之间？这个灰色地带形成了一个通常被称为创新疗法的过渡区。鉴于当前创新格局的复杂性，创新疗法委员会可能提供一种机制，帮助医生和患者应对诸如知情同意过程、管理利益冲突以及如何评估创新疗法结果等难题。由于外科创新对医疗进步仍然至关重要，它必须在与患者的透明合作关系中进行，在指导实体的监督下，最终目标是改善治疗结果和医疗服务。
